Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus

Dapagliflozin is an inhibitor of human renal sodium‐glucose cotransporter 2 (SGLT2), first approved for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin is primarily metabolized by uridine diphosphate glucuronosyltransferase 1A9 (UGT1A9). The effect of UGT1A9 polymorphisms on dapaglif...

Descripción completa

Detalles Bibliográficos
Autores principales: Naagaard, M. Daniel, Chang, Roy, Någård, Mats, Tang, Weifeng, Boulton, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305486/
https://www.ncbi.nlm.nih.gov/pubmed/34687551
http://dx.doi.org/10.1111/bcp.15117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305486/
https://www.ncbi.nlm.nih.gov/pubmed/34687551
http://dx.doi.org/10.1111/bcp.15117

Ejemplares similares